Nigeria’s already fragile healthcare delivery system faces renewed assaults from multiple directions. Frequent disease outbreaks, reliance on imported medicines, the exodus of medical professionals, and a flood of fake and substandard drugs are causing illnesses, disabilities, and deaths across Nigeria and other West African nations. The government must urgently revitalize its strategy to protect citizens from the scourge of counterfeit medicines.
Outbreaks of cholera, Lassa fever, diphtheria and other diseases are compounding the misery of Nigerians, especially given the weakness of the health system. A new United Nations Office on Drugs and Crime report highlights the gravity of the problem: substandard drugs kill 500,000 people in sub‑Saharan Africa each year. Of these, 267,000 deaths are linked to falsified or substandard anti‑malarial medicines, and up to 169,271 deaths are associated with counterfeit antibiotics used to treat severe pneumonia in children. Recent alerts from the National Agency for Food and Drug Administration and Control (NAFDAC) warn of adulterated cough syrups, antibiotics and other children’s remedies on the market.
Counterfeit drugs are a growing global threat, particularly in developing nations where supply‑chain security is limited, undermining progress toward the UN’s Sustainable Development Goals. While experts estimate that about 10 % of drugs worldwide are fake, a 2017 study in Bayero University’s Journal of Basic and Clinical Sciences suggested that 41–50 % of drugs in Nigeria were substandard. NAFDAC, however, claims the prevalence is no more than 15 %. The World Health Organization (WHO) notes that, on average, one in ten medical products circulating in developing nations is substandard, underscoring the need for stronger action.
Effective monitoring, surveillance, testing, intelligence and interdiction are essential, but special attention must be given to disrupting the sources, transport routes and distribution outlets of counterfeit medicines. Evidence indicates that the majority of dangerous drugs originate from China and India, necessitating close collaboration among regulators, security forces and diplomatic agencies. Nigeria should send a clear message to these countries that it will no longer tolerate being a dumping ground for lethal medicines.
Africa bears a disproportionate share of the problem. Of all fake‑drug reports to the WHO between 2013 and 2017, 42 % came from the African region. In March 2019, the WHO issued alerts about fake meningitis vaccines in Niger and counterfeit hypertension drugs in Cameroon. In August, falsified Augmentin was discovered in Uganda and Kenya. The WHO estimates that treating patients who have used falsified or substandard malaria medicines in sub‑Saharan Africa costs between $12 million and $44.7 million annually. Nigeria accounted for 31 % of global malaria deaths in 2021, with fake malaria drugs contributing to the toll.
International law‑enforcement operations seized more than 605 tonnes of medical products in West Africa between January 2017 and December 2021, yet this is insufficient. Counterfeit medicines inflict both health and economic damage, draining resources from healthcare systems and killing thousands, especially in vulnerable communities. Federal and state governments must continuously develop innovative anti‑counterfeiting measures to secure the medicine supply chain, emphasizing domestic production and self‑sufficiency in essential, life‑saving drugs.
Poor drug traceability—stemming from inadequate infrastructure, insufficient resources for routine quality control, and weak cross‑border tracking—hampers efforts to combat counterfeit medicines. The UN cites porous national borders as a key factor in the booming counterfeit drug trade. Africa’s lack of official data collection on counterfeit medicines and the separation of healthcare and anti‑corruption policies further enable traffickers. International calls for harsher penalties for drug fakers are growing louder, particularly in Nigeria. The government must enact legislation imposing tougher criminal penalties and enforce them to deter counterfeiters and restore integrity to the medicine supply chain.
Beyond China and India, Pakistan and the United Kingdom also constitute major drug‑supply chains to Nigeria. Many Nigerian pharmaceutical companies now act merely as marketers or distributors of foreign‑produced drugs. A shift toward promoting “made‑in‑Nigeria” pharmaceuticals—through incentives and a more favorable business environment—is essential. Under the late Dora Akunyili’s leadership, NAFDAC’s vigorous fight against fake drugs earned international acceptance for domestically manufactured medicines, boosting demand, production capacity and GDP. Replicating this success should be a national priority.
To achieve this, governments must address infrastructure deficits, eliminate multiple taxes and levies, and resolve energy crises that add roughly 40 % to production costs, according to manufacturers. NAFDAC must rise to the challenge by delivering its five‑year Traceability Implementation Plan, aligned with the Nigeria Pharmaceutical Traceability Strategy, to achieve supply‑chain visibility and strengthen interventions against substandard and falsified medicines. Close collaboration among all stakeholders—regulators, professional and trade associations, producers, importers and security agencies—is vital. Safeguarding Nigerians from the deluge of fake drugs must become a national priority.
Comments are closed for this story.